TY -的T1 -开关抗癫痫药物后发作的结果:一个匹配,前瞻性研究(S31.005) JF -神经学乔-神经学六世- 84 - 14补充SP - S31.005盟Jon Finamore AU -迈克尔·斯珀林盟婷婷詹AU 首页-克里斯托弗•斯基德莫尔盟Maromi Nei AU -斯科特·明茨Y1 - 2015/04/06 UR - //www.ez-admanager.com/content/84/14_Supplement/S31.005.abstract N2 -目的:调查结果改变后的抗癫痫药物(aed)局灶性癫痫患者在控制,未来的时尚。背景:改变AED治疗后结果很大程度上是在案例学习系列。我们组最近报道首次研究检查控制方式。在这里,我们报告的结果改变AED疗法,在耐火材料的病人和那些在缓解,AED,使用一种改进的控制,前瞻性研究设计。设计/方法:我们发现局灶性癫痫患者采取单一AED看到在我们中心的九个月的时间。切换到另一台AED的单一疗法被认为是病人,而那些仍在同一药物作为控制。我们匹配情况下控制基于癫痫状态(癫痫发作前6个月),当前AED,和之前AED的数量。我们前瞻性地遵循这些病人和重新发作状态在6个月后,索引日期。结果:患者在控制发作了药物(n = 13), 15.4 (percnt)反复发作,相比7.7 [percnt]复发之间的控制保持在同一药物(n = 39;p = 0.59)。 Among non-seizure-free patients who switched drugs (n=29), 41.4[percnt] had a 6-month remission, compared to 55.2[percnt] controls remaining on the same drug (n=29; p=0.43). Those who had tried 2 or more other AEDs in the past were less likely to enter remission than those who had tried 1 or none (p=0.015). CONCLUSIONS:For seizure-free patients, we found a modest, non-significant risk (~8[percnt]) of seizure recurrence associated with changing medication. Non-seizure-free patients were at least as likely to enter remission on the same drug as with a different drug, suggesting that most positive outcomes in this group are due to spontaneous remission, not drug response.Disclosure: Dr. Finamore has nothing to disclose. Dr. Sperling has received personal compensation for activities with UCB Pharma as a consultant. Dr. Sperling has received personal compensation in an editorial capacity for Epilepsia. Dr. Sperling’s employer has received research support from Sunovion, Ei Dr. Zhan has nothing to disclose. Dr. Skidmore has received personal compensation for activities with Upsher-Smith Laboratories, Inc. as a consultant. Dr. Nei has received research support from Medtronic Inc., Neuropace, GlaxoSmithKline, UCB Pharma, Marinus, and Ortho-McNeil/Johnson & Johnson. Dr. Mintzer has received personal compensation for activities with UCB Pharma, Sunovion, Upsher-Smith Laboratories, Pfizer Inc., SK Pharmaceuticals, Vertex Pharmaceuticals, and Eisai Inc. as a speaker and/or consultant.Wednesday, April 22 2015, 4:00 pm-5:45 pm ER -